新闻源 财富源

2019年10月14日 星期一

康缘药业(600557)公告正文

江苏康缘药业股份有限公司2007年第一季度报告

公告日期:2007-04-18


    1重要提示
    1.1本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    1.2公司全体董事出席董事会会议。
    1.3公司第一季度财务报告未经审计。
    1.4公司负责人肖伟,主管会计工作负责人陈友龙及会计机构负责人(会计主管人员)陈友龙声明:保证本季度报告中财务报告的真实、完整。
    2公司基本情况简介
    2.1主要会计数据及财务指标
                                                                                     币种:人民币
                                                                                 本报告期末比上
                                              本报告期末         上年度期末       年度期末增减
                                                                                        (%)
     总资产(元)                             944,088,894.64      938,483,304.14              0.60
     股东权益(不含少数股东权益)(元)         504,257,373.28      486,260,579.77              3.70
     每股净资产(元)                                    3.23                3.12             3.70
                                                                                 比上年同期增减
                                                     年初至报告期期末
                                                                                        (%)
     经营活动产生的现金流量净额(元)                               15,332,604.16            69.85
     每股经营活动产生的现金流量净额(元)                                   0.098            69.85
                                                                                 本报告期比上年
                                                报告期       年初至报告期期末
                                                                                   同期增减(%)
     净利润(元)                              18,021,130.26        18,021,130.26             9.12
     基本每股收益(元)                                 0.115               0.115             9.12
     稀释每股收益(元)                                 0.115               0.115             9.12
                                                                                  增加0.18个百
     净资产收益率(%)                                   3.57                3.57
                                                                                            分点
     扣除非经常性损益后的净资产收益率                                             增加0.07个百
                                                       3.47                3.47
      (%)                                                                                   分点
    非经常性损益项目
                                                                        年初至报告期期末金额
                           非经常性损益项目
                                                                               (元)
     增项
     营业外收入                                                                      805,847.09
     所得税影响                                                                      265,929.54
     小计                                                                            539,917.55
     减项
     营业外支出                                                                       19,788.94
     所得税影响                                                                        6,530.35
     小计                                                                             13,258.59
     非经常性损益合计                                                                526,658.96
    
        2.2报告期末股东总数及前十名无限售条件流通股股东持股表(已完成股权分置改革)
    
                                                                                        单位:股
     报告期末股东总数(户)                                                               7,555
                                前十名无限售条件流通股股东持股情况
               股东名称(全称)                期末持有无限售条件流通股的数量           种类
     全国社保基金一零四组合                                         6,516,942      人民币普通股
     兴和证券投资基金                                               6,251,253      人民币普通股
     汉盛证券投资基金                                               5,392,061      人民币普通股
     中国农业银行-中邮核心优选股票型证
                                                                    5,044,008      人民币普通股
     券投资基金
     连云港康贝尔医疗器械有限公司                                   4,647,146      人民币普通股
     中国银行-易方达策略成长二号混合型
                                                                    4,456,710      人民币普通股
     证券投资基金
     中国工商银行-诺安价值增长股票证券
                                                                    4,114,019      人民币普通股
     投资基金
     中国工商银行-诺安平衡证券投资基金                             4,060,228      人民币普通股
     国泰君安证券股份有限公司                                       3,700,000      人民币普通股
     交通银行-科瑞证券投资基金                                     3,413,389      人民币普通股
    
        3重要事项
        3.1公司主要会计报表项目、财务指标大幅度变动的情况及原因
        √适用  □不适用
        1.截至报告期末,公司资产负债表项目大幅变动的原因分析:
    
                                                                                       单位:元
         项目            2007年3月31日           2006年12月31日            增减额          增减比例
      应收票据         12,405,691.41            27,627,814.98         -15,222,123.57       -55.10%
    
        报告期末,应收票据比期初减少1,522万元,减少-55.10%,主要是报告期公司回款增加现汇结
        算、减少承兑汇票结算所致。
        2.报告期,公司现金流量表项目大幅动变动的原因分析:
    
                                                                                       单位:元
              项目             2007年3月31日        2006年3月31日             增减额         增减比例
     经营活动产生的现金流
                               15,332,604.16        9,027,357.25         6,305,246.91       69.85%
    量净额
     投资活动产生的现金流
                               -27,390,385.53        -6,794,817.43      -20,595,568.10      303.11%
    量净额
     筹资活动产生的现金流
                               -20,620,838.60      -11,090,733.39        -9,530,105.21      85.93%
    量净额
     汇率变动对现金的影响      -24,336.75           -17,307.97              -7,028.78       40.61%
     现金及现金等价物净增
                               -32,702,956.72        -8,875,501.54      -23,827,455.18      268.46%
    加额
    
        (1)报告期末,经营活动产生的现金流量净额比上年同期增加6,305,246.91元,增长69.85%,主要是因为报告期公司加强财务预算控制,部分期间费用减少所致。
        (2)报告期末,投资活动产生的现金流量净额比上年同期减少20,595,568.10元,减少303.11%,主要是因为报告期公司购置了固定资产新增投资所致。
        (3)报告期末,筹资活动产生的现金流量净额比上年同期减少9,530,105.21元,减少85.93%,主要是因为报告期公司加强资金管理,减少银行借款所致。
        (4)报告期末,汇率变动对现金的影响比上年同期减少7,028.78元,减少40.61%,主要是因为报告期子公司-康缘国际实业有限公司的港币兑换人民币的汇率变动所致。
        (5)报告期末,现金及现金等价物净增加额比上年同期减少23,827,455.18元,减少268.46%,主要是因为报告期公司购置固定资产、偿还银行借款所致。
        3.2重大事项进展情况及其影响和解决方案的分析说明
        □适用  √不适用
        3.3公司、股东及实际控制人承诺事项履行情况
        √适用  □不适用
        公司第一大股东连云港康缘集团有限公司在《股权分置改革方案》中的承诺:自所持公司非流通股份获得上市流通权之日起,在36个月内不上市交易或者转让;在上述期限届满之日起的24个月内,只有当公司股票价格连续10个交易日的收盘价格高于每股10元后,方可通过证券交易所挂牌交易出售原所持非流通股份(如遇公司分红、送股、转增股本、配股、增发等导致股价除息或除权的,上述收盘价格进行相应调整)。报告期内该股东严格遵守承诺,没有发生转让我公司股份的行为。
        3.4预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明
        □适用  √不适用
        3.5本次季报资产负债表中的2007年期初股东权益与“新旧会计准则股东权益差异调节表”中的2007年期初股东权益存在差异的原因说明:
        □适用  √不适用
        江苏康缘药业股份有限公司
        法定代表人:肖伟
        2007年4月17日
        4附录
        资产负债表(一)
        2007年3月31日
        编制单位:江苏康缘药业股份有限公司                                单位:元币种:人民币审计类型:未经审计
    
                                                           合并                                 母公司
                    项目
                                               期末余额           年初余额           期末余额            年初余额
     流动资产:
     货币资金                                112,945,814.74     145,648,771.46       68,578,771.91     111,482,517.19
     交易性金融资产
     应收票据                                 12,405,691.41      27,627,814.98        6,300,582.13      23,790,013.54
     应收账款                                238,054,727.08     201,913,523.15      164,512,937.67     128,635,074.20
     预付款项                                  4,672,793.51       4,235,366.19        4,562,849.47       2,704,285.16
     应收利息
     应收股利
     其他应收款                               49,634,065.34      46,986,167.27       35,187,933.28      34,725,505.41
     存货                                     54,325,805.85      50,389,901.63       36,772,783.55      36,580,160.31
     一年内到期的非流动资产
     其他流动资产
     流动资产合计                            472,038,897.93     476,801,544.68      315,915,858.01     337,917,555.81
     非流动资产:
     可供出售金融资产
     持有至到期投资
     长期应收款
     长期股权投资                             23,170,897.12      22,739,405.48       69,089,791.15      68,658,299.51
     投资性房地产                              8,454,479.31       8,692,845.42       16,584,271.53      16,725,635.88
     固定资产                                370,794,250.91     357,611,554.56      345,160,767.64     331,529,669.40
     在建工程                                    828,598.35         347,290.00          828,598.35         347,290.00
     工程物资
     固定资产清理
     生产性生物资产
     油气资产
     无形资产                                 65,749,519.52      68,759,781.86      37,666,011.07       40,676,273.41
     开发支出
     商誉
     长期待摊费用                                760,584.80       1,130,829.05          507,772.17         812,435.10
     递延所得税资产                            2,291,666.70       2,400,053.09        2,179,965.53       2,284,865.40
     其他非流动资产
     非流动资产合计                          472,049,996.71     461,681,759.46      472,017,177.44     461,034,468.70
     资产总计                                944,088,894.64     938,483,304.14      787,933,035.45     798,952,024.51
    公司法定代表人:肖伟                       主管会计工作负责人:陈友龙                  会计机构负责人:陈友龙
    
        资产负债表(二)
        2007年3月31日
        编制单位:江苏康缘药业股份有限公司                                单位:元币种:人民币审计类型:未经审计
    
                                                           合并                                 母公司
                    项目
                                               期末余额           年初余额           期末余额            年初余额
     流动负债:
     短期借款                                144,500,000.00     158,500,000.00      105,000,000.00     125,000,000.00
     交易性金融负债
     应付票据                                 10,000,000.00      12,171,857.00       10,000,000.00      10,000,000.00
     应付账款                                127,301,829.89     119,332,117.64       42,878,654.13      45,458,784.55
     预收款项                                  1,190,623.89       1,320,850.81
     应付职工薪酬                              8,861,272.95       8,669,764.25        4,137,141.36       4,881,220.69
     应交税费                                 15,853,184.07      13,912,930.45       13,736,586.17      11,100,562.26
     应付利息
     应付股利
     其他应付款                               54,097,301.89      57,225,234.04       41,611,663.36      44,669,444.46
     一年内到期的非流动负债                   10,350,000.00      13,800,000.00       10,350,000.00      13,800,000.00
     其他流动负债                             13,260,500.00      13,260,500.00       13,260,500.00      13,260,500.00
     流动负债合计                            385,414,712.69     398,193,254.19      240,974,545.02     268,170,511.96
     非流动负债:
     长期借款                                 45,000,000.00      45,000,000.00       45,000,000.00      45,000,000.00
     应付债券
     长期应付款
     专项应付款
     预计负债
     递延所得税负债
     其他非流动负债
     非流动负债合计                           45,000,000.00      45,000,000.00       45,000,000.00      45,000,000.00
     负债合计                                430,414,712.69     443,193,254.19      285,974,545.02     313,170,511.96
     所有者权益:
     实收资本                                156,060,000.00     156,060,000.00      156,060,000.00     156,060,000.00
     资本公积                                168,159,661.95     168,159,661.95      167,594,263.83     167,594,263.83
     减:库存股
     盈余公积                                 41,253,824.63      41,253,824.63       41,253,824.63      41,253,824.63
     未分配利润                              138,894,554.35     120,873,424.09      137,050,401.97     120,873,424.09
     外币报表折算差额                           -110,667.65         -86,330.90
     归属于母公司所有者权益合计              504,257,373.28     483,975,714.37
     少数股东权益                              9,416,808.67       9,029,470.18
     所有者权益合计                          513,674,181.95     495,290,049.95      501,958,490.43     485,781,512.55
     负债和所有者权益合计                    944,088,894.64     938,483,304.14      787,933,035.45     798,952,024.51
    公司法定代表人:肖伟                       主管会计工作负责人:陈友龙                  会计机构负责人:陈友龙
    
        利润表
        2007年3月31日
        编制单位:江苏康缘药业股份有限公司                                单位:元币种:人民币审计类型:未经审计
    
                                                                 合并                                母公司
                       项目
                                                     本期金额          上期金额           本期金额           上期金额
     一、营业收入                                 220,554,625.22      220,241,752.40    130,271,223.83     126,374,563.28
     减:营业成本                                  101,250,383.42      95,014,387.20     34,836,382.90      27,473,202.76
     营业税金及附加                                  2,373,608.00       2,495,000.01      2,003,651.44       2,054,557.55
     销售费用                                       67,586,835.72      73,073,326.89     50,880,514.77      56,384,343.71
     管理费用                                       21,245,792.51      20,092,600.15     18,043,649.46      14,788,957.27
     财务费用                                        3,753,482.10       4,504,586.27      3,174,668.09       3,778,738.01
     资产减值损失                                      -83,193.14         355,853.20        -83,890.76         324,409.02
     加:公允价值变动收益
     投资收益                                          431,491.64         421,648.88        431,491.64         421,648.88
     其中:对联营企业和合营企业的投资收益
     二、营业利润                                  24,859,208.25       25,127,647.56     21,847,739.57      21,992,003.84
     加:营业外收入                                    805,847.09           6,000.00        450,000.00
     减:营业外支出                                     19,788.94          37,709.51
     其中:非流动资产处置净损失
     三、利润总额                                  25,645,266.40       25,095,938.05     22,297,739.57      21,992,003.84
     减:所得税费用                                  7,247,674.77       8,136,352.38      6,120,761.69       7,118,217.13
     四、净利润                                    18,397,591.63       16,959,585.67     16,176,977.88      14,873,786.71
     归属于母公司所有者的净利润                     18,021,130.26      16,514,647.71
     少数股东损益                                      376,461.37         444,937.96
     五、每股收益:
     (一)基本每股收益                                    0.1155             0.1058
     (二)稀释每股收益                                    0.1155             0.1058
    公司法定代表人:肖伟                       主管会计工作负责人:陈友龙                  会计机构负责人:陈友龙
    
        现金流量表
        2007年1-3月
        编制单位:江苏康缘药业股份有限公司                                  单位:元币种:人民币审计类型:未经审计
    
                                                             合并                                母公司
                     项目
                                                本期金额            上期金额           本期金额          上期金额
     一、经营活动产生的现金流量:
     销售商品、提供劳务收到的现金              212,177,709.04     225,068,644.42     110,025,068.44    117,949,903.84
     收到的税费返还                                610,107.76         665,339.32
     收到的其他与经营活动有关的现金                615,490.38         649,771.91         536,462.30        112,894.51
     经营活动现金流入小计                      213,403,307.18     226,383,755.65     110,561,530.74    118,062,798.35
     购买商品、接受劳务支付的现金               89,537,374.66      96,696,487.62      16,170,498.57     18,188,867.54
     支付给职工以及为职工支付的现金             23,977,017.16      20,301,925.83      17,929,882.00     13,561,944.34
     支付的各项税费                             29,942,373.57      32,603,562.08      24,141,381.33     27,074,688.20
     支付的其他与经营活动有关的现金             54,613,937.63      67,754,422.87      41,748,867.67     49,119,382.17
     经营活动现金流出小计                      198,070,703.02     217,356,398.40      99,990,629.57    107,944,882.25
     经营活动产生的现金流量净额                 15,332,604.16       9,027,357.25      10,570,901.17     10,117,916.10
     二、投资活动产生的现金流量:
     收回投资所收到的现金
     取得投资收益所收到的现金
     处置固定资产、无形资产和其他长期
                                                   109,589.00
     资产收回的现金净额
     处置子公司及其他营业单位收到的现
     金净额
     收到的其他与投资活动有关的现金
     投资活动现金流入小计                          109,589.00
     购建固定资产、无形资产和其他长期
                                               27,499,974.53        6,794,817.43      27,473,974.53      6,236,073.42
     资产支付的现金
     投资所支付的现金                                                                                    2,182,113.00
     取得子公司及其他营业单位支付的现
     金净额
     支付其他与投资活动有关的现金
     投资活动现金流出小计                       27,499,974.53       6,794,817.43      27,473,974.53      8,418,186.42
     投资活动产生的现金流量净额                -27,390,385.53      -6,794,817.43     -27,473,974.53     -8,418,186.42
     三、筹资活动产生的现金流量:
     吸收投资所收到的现金
     其中:子公司吸收少数股东投资收到
     的现金
     取得借款收到的现金                         91,000,000.00       1,000,000.00      85,000,000.00
     收到其他与筹资活动有关的现金                                     150,000.00                           150,000.00
     筹资活动现金流入小计                       91,000,000.00       1,150,000.00      85,000,000.00        150,000.00
     偿还债务支付的现金                        108,450,000.00       7,900,000.00     108,450,000.00      3,400,000.00
     分配股利、利润或偿付利息支付的现
                                                3,170,838.60        4,340,733.39       2,550,671.92      3,578,575.00
     金
     其中:子公司支付给少数股东的股
     利、利润
     支付其他与筹资活动有关的现金
     筹资活动现金流出小计                     111,620,838.60       12,240,733.39    111,000,671.92       6,978,575.00
     筹资活动产生的现金流量净额               -20,620,838.60      -11,090,733.39    -26,000,671.92      -6,828,575.00
     四、汇率变动对现金及现金等价物的
                                                   -24,336.75         -17,307.97
     影响
     五、现金及现金等价物净增加额             -32,702,956.72       -8,875,501.54    -42,903,745.28      -5,128,845.32
     加:期初现金及现金等价物余额             145,648,771.46      157,574,849.75    111,482,517.19     121,757,840.65
     六、期末现金及现金等价物余额             112,945,814.74      148,699,348.21     68,578,771.91     116,628,995.33
    公司法定代表人:肖伟 
    主管会计工作负责人:陈友龙  
    会计机构负责人:陈友龙